EGFR and neoplasm: IGF-1R exhibits crosstalk with EGFR and mediates tumour resistance to EGFR inhibitors, and a phase II clinical trial (NCT00769483) showed that MK-0646, an IGF-1R antagonist, synergistically improved OS when applied with gemcitabine (10.4 months vs 5.7 months, P value = 0.02) [52].